Adaptin Bio Flags Going Concern, Material Weaknesses in Q2 10-Q
APTN is trading near its 52-week low of $5.6 (12% above the low).
Summary
Adaptin Bio's Q2 10-Q discloses going concern doubt, material weaknesses, and ongoing dilution from warrant exercises and private placements.
Key Events · Earnings and Guidance · APTN
-
Going Concern Doubt
Management states substantial doubt about the company's ability to continue as a going concern, with cash of $670,488 and accumulated deficit of $11,643,209 as of June 30, 2026.
-
Material Weaknesses Persist
Material weaknesses in internal control over financial reporting, including errors in non-routine transactions, prepaid/accrued R&D costs, and tax provisions, continued as of June 30, 2026.
-
Follow-on Offering Closings
Completed three closings in Q2 2026: February 12 ($297,000), March 12 ($355,000), and June 9 ($260,000), all at $5.00 per share, totaling $912,000 gross proceeds.
-
Warrant Exercises Add Dilution
Received $726,227 and issued 165,050 shares from A Warrant exercises in Q2 2026; subsequent to June 30, 2026, received $739,964 and issued 168,173 shares from A Warrants, plus $39,999 and 12,121 shares from Exchange Warrants.
Analysis · APTN · Life Sciences
Adaptin Bio's Q2 10-Q reveals substantial doubt about its ability to continue as a going concern, with only $670,488 in cash and an accumulated deficit of $11.6 million. The company also disclosed continued material weaknesses in internal controls. These are critical red flags for a pre-revenue biotech with no approved products.
At the time of this filing, APTN was trading at $6.27 on OTC in the Life Sciences sector. The 52-week trading range was $5.60 to $6.27. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.